Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryFAQAbout
TEVA - Teva- Pharmaceutical Industries Ltd.
0.25(3.20%)8:00:02 PM 9/30/2022
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.


  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
Stock Statistics
PE Ratio-8.5
PEG Ratio0.7
P/S (ttm)0.7
Earning Growth (QoQ)12%
Revenue Growth (QoQ)
Short %0%
Held by Institutions %53%
1 Day Vol Adjusted Return1.6
1 Month Vol Adjusted Return-5.4
3 Month Vol Adjusted Return0.5
6 Month Vol Adjusted Return-3.8
20 Days SMA Price ZScore-0.9
50 Days SMA Price ZScore-1.1
12 -26 Days PPO-4.7
1 Month Average Short Volume Ratio49.5
1 Day Volume Change ZScore0.3
1 Month Daily Vol2.0
Related Topics

Stock news

    Why Teva Stock Shot More Than 3% Higher Today

    Teva Pharmaceutical Industries (NYSE: TEVA) stock closed the trading week in style, rising by over 3% on a bleak and bearish day for the wider market. Teva Pharmaceuticals, the company's key subsidiary, has reached an agreement with the southern state's attorney general to settle accusations of price-fixing. Under the terms of the arrangement, Teva is to pay just under $3.35 million; in return, once the funds are handed over Georgia will dismiss all claims against the company in the case.

    Teva Reaches Agreement With Georgia to Settle the State’s Price Fixing Claims

    TEL AVIV, Israel & PARSIPPANY, N.J., September 30, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached an agreement with the Attorney General (AG) of Georgia to settle the state’s price-fixing claims against Teva. Teva will pay the state $3.346 million as part of the settlement, and the state will dismiss all of its claims against Teva and its affiliates once payment has been made.

    European Drug Makers Say Higher Energy Costs Eating Margins: Report

    Europe's drug makers have warned about stopping manufacturing some cheap generic medicines amid surging electricity costs. The generic drug industry lobby group, Medicines for Europe, representing Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Novartis AG's (NYSE: NVS) Sandoz unit, and Fresenius SE's (OTC: FSNUY) Kabi business, sent a letter to European states' energy and health ministers, asking for measures to relieve the cost burden. According to Medicines for Europe, Generic associations p

    Teva Launches Honestly HD Website to Provide People Living With Huntington’s Disease (HD) Information, Inspiration and Resources on HD Chorea

    TEL AVIV, Israel & PARSIPPANY, N.J., September 26, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of the Honestly HD website, which aims to provide information, inspiration and resources to help people understand what to expect with Huntington’s Disease (HD) chorea – one of the most visible and treatable symptoms of HD – and, how to talk to their doctor about preserving independence. In addition to the newly l

    Op-Ed: Prevent a legal catch-22 that could push thousands of generic drugs off the market

    To avert a collision of patents and safety regulations, the Supreme Court must ensure that a damaging ruling is quickly undone.

    Teva To Start Nationwide Settlement Of Opioid Lawsuits From Next Year: Report

    Reuters reported that Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) CEO said the company will finalize the U.S. opioid settlement by the end of 2022 and start paying in 2023. CEO Kare Schultz also said he was unlikely to renew his contract next year. In its Q2 earnings release, Teva proposed a $4.35 billion settlement - mostly cash and partly medicines over 13 years - to resolve its opioid lawsuits. Related: New York Attorney General Says Teva Tried To Evade Accountability On Opioid Crisis.

    UPDATE 2-Teva Pharm expects to start paying U.S. opioid settlement in 2023 - CEO

    Teva Pharmaceutical Industries expects to finalise an opioid settlement in the United States by year-end and start paying in 2023, its chief executive said on Sunday, while confirming he was unlikely to renew his contract next year. After years of negotiations, Israel-based Teva in July proposed a $4.35 billion nationwide settlement - mostly cash and partly medicines that will amount to $300 million to $400 million over 13 years - to resolve its opioid lawsuits. CEO Kare Schultz said Teva was ...